Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade,
but its treatment benefits are limited by acquired resistance, a process that remains …

The DNA repair protein O6‐Methylguanine‐DNA methyltransferase (MGMT) is suggested to
be associated with resistance to alkylating agents such as Temozolomide which is being …

Glioblastoma is the most common and most aggressive primary brain tumor. Despite
maximum treatment, patients only have a median survival time of 15 months, because of the …

Seizures are common in patients with brain tumors, and epilepsy can significantly impact
patient quality of life. Therefore, a thorough understanding of rates and predictors of …

High-grade gliomas (HGGs) account for the vast majority of all gliomas, including
glioblastoma (World Health Organization (WHO) grade IV) and anaplasticgliomas (WHO …

Purpose Symptomatic epilepsy is a common complication of glioblastoma and requires
pharmacotherapy. Several uncontrolled retrospective case series and a post hoc analysis of …

Epilepsy often develops in patients with glioma, and the two conditions share common
pathogenic mechanisms. Altered expression of glutamate transporters, including the cystine …

Brain tumor-related epilepsy (BTE) is common in low-and high-grade gliomas. The risk of
seizures varies between 60% and 100% among low-grade gliomas and between 40% and …